AUSTIN, Texas, Nov. 3, 2011 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has received a notice of allowance from the United States Patent and Trademark Office for its fifth patent covering a combination of biomarkers that could be used in the diagnosis of Peripheral Artery Disease (PAD), a condition that raises the risk of heart attack and stroke.
The patent, entitled "Beta-2 Microglobulin (B2m) and C Reactive Protein (CRP) as Biomarkers for Peripheral Artery Disease," involves a unique combination of B2m and CRP, two proteins that have been demonstrated in numerous studies to be associated with PAD.
"This patent substantially strengthens our IP portfolio around the development of VASCLIR®, our product under development for diagnosing PAD," said Dr. Eric Fung, Vermillion's chief medical officer, "and the notice of allowance follows the promising top line results we achieved from our recently completed intended use study."
The goal of the study was to develop and validate a biomarker panel applicable to the intended use population. The results have yielded significant insights regarding individual biomarkers. The details of the study and its results will be made public via a formal presentation at an upcoming cardiovascular meeting.
"This study is an important advancement, " noted Dr. Fung, "since according to the U.S. Department of Health and Human Services, one in every 20 Americans over the age of 50 has PAD."(1)
For additional information about Vermillion, contact Liolios Group at 949-574-3860 or email email@example.com.
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercializatio
|SOURCE Vermillion, Inc.|
Copyright©2010 PR Newswire.
All rights reserved